Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) released its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08), Zacks reports. The business had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%.
Intra-Cellular Therapies Stock Performance
ITCI traded down $0.05 on Tuesday, reaching $128.53. The company had a trading volume of 1,466,076 shares, compared to its average volume of 4,048,619. Intra-Cellular Therapies has a 52-week low of $63.30 and a 52-week high of $128.77. The company has a market cap of $13.67 billion, a price-to-earnings ratio of -147.73 and a beta of 0.72. The business has a 50 day simple moving average of $111.14 and a 200 day simple moving average of $90.22.
Wall Street Analyst Weigh In
A number of analysts recently commented on ITCI shares. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday. Baird R W lowered Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. StockNews.com began coverage on Intra-Cellular Therapies in a research note on Monday. They set a "hold" rating on the stock. Finally, JPMorgan Chase & Co. increased their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a report on Monday, November 4th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $106.08.
Get Our Latest Research Report on ITCI
Insiders Place Their Bets
In other news, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 2.60% of the company's stock.
About Intra-Cellular Therapies
(
Get Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Featured Articles
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
